Asset sale Pending
ESTEVE acquisition of TerSera Infusion Specialty Therapies Business Unit (IST)
Announced 13 Jan 2026
Advisers
TerSera Infusion Specialty Therapies Business Unit (IST)
Target
- Financial adviser
- Legal adviser
- Target
- TerSera Infusion Specialty Therapies Business Unit (IST)
- Acquirer
- ESTEVE
- Seller
- TerSera Therapeutics
- Target based in
- United States (unverified)
- Buyer based in
- Spain
- Seller based in
- United States
- Sector
- Pharma
In the league tables
Similar deals
- Fresenius acquisition of mAbxience Oct 2026 · US$1.9bn · Biotech
- Gilead acquisition of HCXT-2001 (investigational oral IL-23R inhibitor) Oct 2026 · Pharma
- US WorldMeds acquisition of Orbus Therapeutics Oct 2026 · Pharma
- DRI Healthcare Trust acquisition of Royalty participation rights in U.S. net sales of tavapadon Sep 2026 · US$316m · Specialty finance and leasing
- Grünenthal acquisition of Stivarga (regorafenib) Sep 2026 · US$433m · Pharma
Sources
- Jan 2026 Kirkland Advises TerSera Therapeutics on Sale of Infusion Specialty Therapies Business Unit to ESTEVE kirkland.com
- Jan 2026 Perella Weinberg Partners: Exclusive financial advisor to ESTEVE on its acquisition of TerSera Therapeutics’ Infusion Specialty Therapies Business Unit Undisclosed pwpartners.com
- 13 Jan 2026 Press release (PR Newswire), ESTEVE to acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit, Expanding U.S. presence prnewswire.com


